Search results

Memorises Bio is a therapeutic antibody discovery company spun out of Memo Therapeutics. We investigate human immune responses and translate them into therapeutic antibodies, combining deep repertoire capture with large-scale functional screening.

Xlife Sciences is a publicly listed life sciences incubator and accelerator. Xlife is focused on the value development and commercialization of promising research projects from universities and other research institutions. The goal is to bridge research and development to healthcare markets.

Based in Epalinges, Pilatus Biosciences focuses on developing a first-in-class antibody targeting metabolic checkpoints. The company is transforming cancer treatment by developing innovative therapies that strengthen the immune system to fight cancer.

Zürich-based health technology company building clinical AI for European primary care. The Jupiter Ecosystem connects an EHR, a patient app and Dia, an AI clinical reasoning layer: AI proposes, the physician decides. ahtida’s live digital clinic is the proprietary data engine.

FIDAI is an AI data intelligence platform streamlining biotech due diligence. We help founders organize complex preclinical and clinical data into audit-ready data rooms, cutting investor review times from months to weeks and bridging the gap between scientific discovery and venture capital.

We bring the most sensitive biophysical assays to the high-throughput screening world. Our integrated biophysics platform combines lab automation with on-the-fly data analysis, allowing our customers to screen up to a million compounds within weeks, harnessing the power of direct binding assays.

Step Pharma is a clinical stage precision oncology company. Dencatistat (STP938) is a first in class, oral, selective CTPS1 inhibitor currently in Phase I/II clinical development in essential thrombocythemia, biomarker selected solid tumours and relapsed/refractory lymphoma.

imunaris is a forward-thinking Swiss startup committed to facilitating commercial access for pharmaceuticals, medical devices, and diagnostics. With a focus on agile and efficient methods, we offer tailored solutions to conquer the complexities of the Swiss healthcare market.

nuantic offers AI-guided lead optimization to biotech and pharma customers developing protein- and peptide-based therapeutics. We're able to optimize affinity, developability and aspects of immunogenicity with outstanding success rates with 10x less effort as compared to traditional methods.

FoRx Therapeutics is a clinical-stage company that develops next-generation small molecule therapeutics targeting DNA Replication Stress pathways for anti-cancer therapy. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which  moved into clinical Phase 1 in H2 2025.

arcoris bio develops next-generation technologies for biomarker detection in research and diagnostics. Its flagship MUSE platform provides universal, programmable signal amplification to enable highly sensitive and multiplex assays that drive the future of digital pathology.

Humion is a Swiss cancer therapeutics biotech developing TCR-based T-cell therapies for solid tumors. We decode the immune responses of cancer super responders to identify validated tumor targerts and translate them into precise, patient-derived therapeutics.

Solvias is a Contract Research, Development & Manufacturing Organization We offer comprehensive, high quality and fast analytical services for small molecule API, biologics and cell & gene therapies, by ensuring the interplay of outstanding experts in every required individual discipline.

dEEGtal develops AI-driven solutions to enhance EEG analysis, starting with a medical device for epilepsy diagnosis. While focused on clinical applications, we are expanding to offer AI models that provide deeper insights into EEG data for neuroscience, pharma, and industry partners.

ADM is a global leader in both human and animal nutrition. With industry-advancing innovations, a complete portfolio of ingredients and solutions to meet any taste, and a commitment to sustainability, we give customers an edge in solving the nutritional challenges of today and tomorrow.

We are a seed-stage biotech company dedicated to relentlessly pursuing functional cures for rare disease patients and their families. With an initial focus on rare diseases, we aim to expand our scope to include genetically defined common diseases in the future.

Jantar is a clinical R/D company in the field of chronic rhinosinusitis. Its asset is dicholine succinate for which clinical proof-of-concept has been established. DISU represents a differentiated new drug with strong safety, rapid efficacy and clear potential for global consumer health leadership.

We are a leading international company offering end-to-end solutions ranging from the automation, process engineering and validation of biotech and pharmaceutical plants. With more than two decades of experience in GMP environments, we have in-depth knowledge of the applicable regulations.  

At Labocare, our team is dedicated to ensuring the quality and reliability of your laboratory equipment through extensive experience and unwavering commitment. Our personnel includes certified service engineers and a management team with extensive years of experience in the industry.  

Hippocrates Research Swiss offers a boutique CRO model built on 30 years of experience. With a lean, agile structure and senior-level involvement, we transform scientific innovation into strong clinical assets, delivering capital efficiency, strategic focus, and measurable value.

Business Strategy and Development Partner in the Life Science Industry with over 30 years of experience in Pharma, Pharma Chemistry and Biotech.  

Hemastatx brings innovation to patients with severe, underserved bleeding conditions. HMX-001 is a first-in-class anti-ADAMTS13 antibody targeting the root cause of severe bleeds in (rare) von Willebrand factor (VWF) disorders. Hemastatx is a KU Leuven spinoff and part of the BaseLaunch portfolio.

Preclinical stage biopharmaceutical company, spin off of the European Diabetes Study Center (CeeD), dedicated to developing first-in-class biotherapies against diabetes and metabolic diseases, harvesting the breakthrough potential of the muscle secretome to regulate metabolism, a novel and unexplored approach

Biodelphis Therapeutics is a Swiss biotech startup, spinoff of EPFL. We developed a new generation of protease inhibitors with enhanced potency and safety, exhibiting all the qualities needed to become first-in-class drugs for the treatment of cancer, autoimmune diseases and bone diseases.

Enabling breakthrough medicines achieve the outcomes they were designed for. We unlock the full therapeutic potential of innovative drug candidates through our next-gen nanomedicine delivery platform. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.

Minaris is a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization. With more than 25 years of CGT development and manufacturing expertise and more than 40 years in biosafety testing, Minaris combines deep legacy experience with state-of-the-art GMP facilities.

Accelsiors is a global, full-service clinical research organization delivering end-to-end trial solutions under one roof. For over 20 years, we’ve supported biopharma with scientific, regulatory, legal, and operational expertise, driving efficient, high-quality clinical development worldwide.

DKSH is a global distribution and strategic solutions partner for life science and industrial specialties. We provide innovative and sustainable pharmaceutical and biopharmaceutical ingredients to manufacturers across Asia, Europe, and North America.

Alp Bio AG is a Swiss biotech startup that combines human immune organoid technology with generative AI. The company provides immunogenicity intelligence to detect and mitigate anti-drug antibody (ADA) risks years before clinical trials, helping developers avoid costly late-stage failures.

Hettich AG, based in Bäch, Switzerland, has supplied laboratory equipment since 1977. We develop and distribute Hettich instruments and represent Memmert, Helmer, B Medical Systems and delta T, supporting life science customers with expertise, reliability and local service.

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.

Headquartered in Switzerland with global operations, Space Peptides provides end-to-end pharmaceutical Peptide CRDMO services - covering discovery, process development, and GMP manufacturing. In addition, our portfolio comprises a broad range of generic Peptide APIs.

Opterion Health AG is a privately owned, Swiss-based, clinical-stage biotech company developing innovative therapies for peritoneal dialysis (PD).

Asemblis is a Swiss biotech company developing scalable, human-relevant in vitro models for obesity and metabolic disorders. The company partners with industry and research organizations to support translational R&D and decision-making in drug development.

Nanolynx Biologics AG is developing first-in-class conditionally active nanobody-drug conjugates (CA-NDCs) that overcome the tissue penetration and toxicity limits of conventional ADCs, enabling safer and more efficacious therapies for hard-to-treat solid tumors.  

AzureCell is a Swiss regenerative cell therapy company leveraging two decades of pioneering neuroscience and cell‑engineering research at the University of Geneva to advance next‑generation allogeneic cell‑replacement therapies for the brain.

Streamlining complexity: with 15+ years experience (EU, US and Far East) in Oncology, Rare Diseases and Quality of Life Assessment, Naexture provides ad-interim leadership roles in Clinical Operations and Program Management to end-to-end operationalize clinical research programs.

GlioCART is a University of Basel spin-off focused on translating a dual-action CAR-T therapy for glioblastoma into clinical application by combining tumor targeting with immune microenvironment reprogramming. Our mission is to achieve durable clinical benefit for patients with glioblastoma.

Stallergenes Greer is a fully integrated global healthcare company specialising in the research, diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services.

Swiss Rockets is dedicated to developing groundbreaking medicines that transform the treatment of cancer, infectious diseases, and autoimmune disorders – advancing more effective, equitable, and accessible healthcare for patients worldwide.

CALDRE is a Switzerland based biotech spin-out focussed to revolutionize the way cholestatic-and fibrotic diseases are treated. We develop precise, liver-directed GalNAc-siRNAs to restore bile flow and prevent fibrosis - placing CALDRE in the fast-growing RNA-therapeutics segment of biotech.

RC TRITEC is an established company offering custom synthesis of tritium-labeled compounds, a range of tritiated catalog products, storage service and disposal of radiochemicals. We have over 60 years of experience in the safe handling of tritium gas using in-house developed high-vacuum equipment.

Almac provides the most comprehensive global clinical supply chain solution in the marketplace. Guided by our extensive supply experience, we provide the physical resources and supportive technologies that ensure your clinical supply chain continually delivers across the globe.

Macrogen Europe GmbH, Swiss branch of Macrogen Europe B.V. (Amsterdam), provides fast, reliable Sanger and NGS sequencing. All sequencing labs are based in Amsterdam and Seoul. We support research and clinical needs across Europe and Africa with advanced genomic and bioinformatics services.

European market entry partner for rare disease, ATMP and cell & gene therapy biotechs

We develop animal-based products via cell cultivation, combining proprietary animal cell biology with scalable bioprocessing at favorable unit economics. The platform starts with the world's first cultivated whole-cut beef and expands into functional applications, like cell-derived collagen.

MoleSense is a multi-award-winning developer of medical wearable technologies. We are creating a new standard for continuous, non-invasive molecular monitoring, turning the body’s chemistry into real-time insight that transforms how health is predicted, prevented, and managed.  

SYDRA AG (Zurich) is a longevity biotech using a phenotype-first, AI-assisted “Hit-to-Target” early drug discovery platform. We discover small molecules (geroprotectors), validate in vivo (worms – aged mice), then map MoA to build partner-ready drug assets; plus science-backed supplements.

Topadur Pharma AG (Schlieren, Zurich) is a clinical-stage biotech company developing small-molecule therapies that target impaired microcirculation and tissue regeneration. Its proprietary DualTOP® platform combines complementary pharmacological activities in single molecules for local use.

Blanc-Labo has been installing and maintaining in Switzerland complex equipments for laboratories for the past 35 years. We have about 4000 customers in Switzerland and France: biotechs, universities, industries. We are based in Lonay near Lausanne.

Mabylon is a clinical-stage company leading innovation in human-derived antibody therapeutics for severe allergies, inflammation, and neurological disorders. MY006, our first-in-class multi-specific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

With 30 years' experience, ICARE stands out as a leader in international standardisation and regulation. We guide healthcare industry through the complex regulatory landscape, ensuring that every healthcare device and product is marketed in full compliance and safety.

Enantios is a Swiss startup revolutionizing molecular characterization with in-solution structural analysis of chiral complex molecules and biologics. Enantios delivers solutions for quality control and drug development in pharmaceutical, biotech, and chemical industries.

AND Biotech is a science-led company developing bioactive technologies that target the core systems of human resilience. We take promising compounds and translate them into clinically meaningful interventions. We develop scalable technologies that address biological decline, starting long before disease.

Antion’s mirGE™ platform enables precise multiplex gene silencing with synthetic miRNAs, allowing independent modulation of up to 7 targets in a single step. Compatible with viral and non-viral delivery, it is designed for scalable, safe and effective ex vivo and in vivo therapies and R&D models.

AxCellerate is a Swiss BioTech company offering pre-clinical research services through its organ-on-chip technologies, using proprietary systems and human-derived cells to to mimic the complexity of the central and peripheral nervous system.

Independent advisor to CDMOs, private equity investors, and biotech companies on strategy, industrialization, and commercialization of advanced therapies and specialized manufacturing platforms, CGT manufacturing strategy, CDMO selection, Support financial investors and PEs with due diligences.

We are specialists for laboratory consumables and pipette service – with a focus on liquid handling. We combine our expertise with a consultative approach so that we can fully understand the daily work of scientists and researchers in order to provide any support needed.

DiNABIOS bridges the gap "from lab to life." We offer human-based screening, phenotyping, and services across diverse tissues. Using proprietary 3D tissue engineering and our DiNAQUBE™ platform, we deliver precise efficacy and safety data to de-risk drug development and accelerate clinical success.

Ultimate Medicine is a Swiss preclinical biotech focused on preserving independence and quality of life for patients with Alzheimer's disease and other dementias.

EVIIVE develops single extracellular vesicle-based diagnostics to predict immunotherapy response and monitor tumor microenvironment in real time. Our platform integrates advanced flow analytics and machine learning for precision oncology applications.

TheraPPI Bioscience is a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases, and inflammation.  

Most cell and stem cell therapies fail beyond blood cancers because delivery cannot preserve function in solid organs. ClexBio’s biological platform enables safe, durable solid tissue replacement, unlocking regenerative therapies for liver failure, type 1 diabetes, and heart disease.

The Future Rewritten: Unlocking Genome Editing. By fusing directed evolution, high-throughput characterization, and AI, Nerai creates novel CRISPR editors, more precise and more powerful, making gene editing safer and accessible to more patients.

AVEctivate supports pharma, biotech and diagnostic companies aiming to make a positive difference to patients, and health care providers by offering strategic consulting, project management and interim management. Believing that change is the only constant, we embrace the future as an opportunity.

Exeris delivers custom solutions to support manufacturing of small molecules and recombinant proteins. We bring our project management, manufacturing and custom synthesis expertise to provide seamless supply to your project.

Tridek-One is a biotech start-up developing first-in-class CD31 agonist modalities designed to restore the immune balance.

Immitra Bio is a pre-seed stage therapeutic biotech company spun out of ETH Zürich. Immitra Bio is developing a platform for scalable, curative in vivo gene-editing therapies.

planetary's proprietary BioBlocks™ platform is powering the bioeconomy and industrial fermentation scale-up for a more sustainable future. We are a biotechnology company licensing a modular fermentation system designed to convert sugar-industry side streams into mycoprotein at industrial scale.

Beech Biotech is developing a novel treatment for preeclampsia, an severe unmet medical need that takes the lives of 70,000 women and 500,000 babies each year. The company is developing a novel placenta-impermeable antibody and works with a network of expert industry consultants and contractors.

XEMPERIA, a spin-off from the University of Fribourg, is pioneering a groundbreaking approach to blood testing that leverages the body's immune response to detect breast cancer at its earliest and most treatable stage.

Umlaut.bio develops first-in-biology small molecules focusing on tRNAs that protect signalling transduction mRNAs from degradation. Addressing this previously undrugged fundamental biochemical principle  could be able to selectively prevent the growth of cancer as well as  proinflammatory cells.

MicThera harnesses microbes to discover breakthrough therapeutics, leveraging microbial bioactive molecules -synthetically produced- to overcome therapy resistance. Our discovery platform unlocks microbial-inspired therapeutics to develop innovative treatments.

Axxam S.p.A. is a CRO delivering integrated early drug discovery, from target identification to lead generation. Through its DiscoveryMAXX platform, it supports pharma, biotech, start-ups, and academia with biology-driven solutions across all therapeutic areas and target classes.

At FloBiotech, we develop advanced human brain cell models to unlock new therapeutic and diagnostic pathways for neurodegenerative diseases. We address neurodegeneration at its core to enable earlier risk reduction in drug development, improved translational success, and scalable pipeline expansion.

Wemedoo AG is a clinical information specialist who specializes in the development of clinical data information systems, as well as data collection, management, analysis, and reporting. We transform healthcare by seamlessly unifying clinical research and clinical practice.

A swiss-based company developing therapeutics for chronic inflammation. We are engineering novel bi-functional Duokine therapeutics, rationally designed to simultaneously target distinct immune cell populations and disease-relevant pathways.

Nxera Pharma is a tech-driven biopharma company focused on specialty medicines for unmet needs in Japan and globally. With 30+ active programs in neurology, GI, immunology, metabolic, and rare diseases, Nxera employs 350+ people across Japan, the UK, Switzerland, and South Korea.

Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. The company targets validated biology in respiratory and dermatology.

Provides consulting services to pharma and biotech clients in market access and pricing area. Support geographic expansion strategies for Asian life sciences companies. Trading in nutraceuticals products for European markets.

TransHeps specializes in iDILI causality assessments, supporting drug developers in clinical trials and managing drug-induced liver injuries. Leveraging cutting-edge expertise, we provide reliable solutions to improve drug safety and accelerate pharmaceutical innovations.

Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development.

metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.

Leman Biotech is a clinical-stage biotech advancing immunotherapy via metabolic reprogramming. Its META 10 platform reverses T-cell exhaustion to unlock unprecedented efficacy and durability in oncology and autoimmune diseases, delivering a highly effective, scalable, and accessible approach.

Pharmabotix leads the way in robot-based automation solutions for the pharma & biotech industry, offering a seamless journey from concept to turnkey implementation. Our products and solutions are distinguished by their cutting-edge innovation, user-friendly simplicity, and space-efficient design.

Philip Morris International (PMI) is a leading international tobacco company with the objective to replace cigarettes with smoke-free products. The goal is to offer adult smokers, who would otherwise continue to smoke, better alternatives that are scientifically substantiated.

Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators.

Abbmira Therapeutics is a Basel-based biotech founded by experienced scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and chronic diseases.

OptoLumina is dedicated to advancing research and promoting the use of optogenetics through cutting-edge illumination technologies. Our flagship product, the Lumiplate, is evidence of our commitment to innovation and quality.

InVirtuoLabs is pioneering the next-generation laboratory by integrating AI with molecular simulations to revolutionize drug discovery. Our platform generates up to 1 billion novel molecules per day, rapidly screening and identifying the most promising ligands for specific biological targets.

Avenza Consulting has been created to support pharma, biotech companies, startups to develop and grow by offering Strategic Consulting, R&D services to foster innovation, Program & Portfolio Management to optimize projects, and Operational Excellence to streamline processes.

Signal26 Biotherapeutics is a biotechnology startup dedicated to advancing a novel antibody for treating psoriasis. In collaboration with interdisciplinary experts, we lead research into interleukin 26 (IL-26) and its role in the signalling pathways involved in autoimmune disorders.

Precise Health develops AI-powered platforms for bacteriophage discovery, host-matching, and engineering. We serve hospitals, biotech, and pharma in the $50B+ anti-infectives and diagnostics markets, addressing the urgent global threat of antimicrobial resistance.

Juvion develops advanced therapeutics aimed at preserving neuron-muscle connectivity, tackling immobility and sarcopenia to extend healthspan.

Release Therapeutics SA (RTx) is a Swiss biotech company developing the first intracerebral encapsulated cell technology (ECT) platform for the treatment of severe genetic disorders of the central nervous system (CNS).

Enzene is a fully integrated CIDMO with sites in Pune (India) & New Jersey (USA), offering discovery to commercial supply. Its EnzeneX™ FCCM™ tech leads next-gen biologics, aiming to cut mAb costs below $40/g by 2025. Learn more at www.enzene.com.